Zobrazeno 1 - 10
of 130
pro vyhledávání: '"Pål A. Holme"'
Autor:
Carmen Escuriola Ettingshausen, Cedric Hermans, Pål A. Holme, Ana R. Cid, Kate Khair, Johannes Oldenburg, Claude Négrier, Jaco Botha, Aurelia Lelli, Jerzy Windyga
Publikováno v:
Therapeutic Advances in Hematology, Vol 14 (2023)
Background: The bypassing agent, activated prothrombin complex concentrate [aPCC, FEIBA (factor VIII inhibitor bypass activity); Baxalta US Inc, a Takeda company, Lexington, MA, USA], is indicated for the treatment of bleeding episodes, perioperative
Externí odkaz:
https://doaj.org/article/8d1f01490a1242c6b4f52dbc1424e3df
Autor:
Pratima Chowdary, Manuel Carcao, Pål A. Holme, Victor Jiménez‐Yuste, Steven R. Lentz, Judi Møss, Lone H. Poulsen, Chunduo Shen, Alberto Tosetto, Allison Wheeler, Elena Santagostino
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 3, Iss 3, Pp 542-554 (2019)
Abstract Background N8‐GP is an extended half‐life recombinant factor VIII developed for prophylaxis and treatment of bleeds in patients with hemophilia A. Objective To assess pharmacokinetic (PK) characteristics of N8‐GP in previously treated
Externí odkaz:
https://doaj.org/article/9e72b2ac203c43c88c631ec0301b622f
Autor:
Christian Qvigstad, Lars Q. Sørensen, Geir E. Tjønnfjord, Pål André Holme, Ingrid Pabinger, Cedric Hermans, Roseline d’Oiron, Robert Klamroth, Johannes Oldenburg, Natascha Marquardt, Peter Staritz, Olga Katsarou, Uri Martinowitz, Aharon Lubetsky, Gili Kenet, Annarita Tagliaferri, Maria Elisa Mancuso, Roger Schutgens, Pål André HolmE, Jerzy Windyga, Irena Zupan, Victor Jimenez Yuste, Ramiro Nunez, Philippe de Moerloose, Erik Berntorp, Jan Astermark, Campbell Tait, Gerry Dolan
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 8, Iss 5, Pp 102514- (2024)
Background: People with hemophilia often experience pain and suffer from comorbidities related to their bleeding disorder. Consequently, unemployment due to disability is prevalent among people with hemophilia. Objectives: To explore associations bet
Externí odkaz:
https://doaj.org/article/bbbcde5173814e1f8d9095c20136a013
Autor:
Christian Qvigstad, R. Campbell Tait, Philippe deMoerloose, Pål Andre Holme, On behalf of the ADVANCE Working Group
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 2, Pp 309-317 (2020)
Abstract Introduction Macroscopic hematuria is considered a significant risk factor for urologic disease, and it is highly prevalent in people with hemophilia. Aim To determine whether prophylactic factor replacement therapy is associated with reduce
Externí odkaz:
https://doaj.org/article/3be73a5323e249469cfa9f5ae973e425
Autor:
Markus Wiedmann, Thor Skattør, Arne Stray-Pedersen, Luis Romundstad, Ellen-Ann Antal, Pål Bache Marthinsen, Ingvild Hausberg Sørvoll, Siw Leiknes Ernstsen, Christian G. Lund, Pål Andre Holme, Tonje Okkenhaug Johansen, Cathrine Brunborg, Anne Hege Aamodt, Nina Haagenrud Schultz, Karolina Skagen, Mona Skjelland
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
During a 2-week period, we have encountered five cases presenting with the combination of cerebral venous thrombosis (CVT), intracerebral hemorrhage and thrombocytopenia. A clinical hallmark was the rapid and severe progression of disease in spite of
Externí odkaz:
https://doaj.org/article/c3587c6c0a5e466a99a915d46b05b264
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 5, Pp n/a-n/a (2021)
Abstract Background Emicizumab is a nonfactor replacement therapy for hemophilia A (HA) and is a bispecific monoclonal antibody mimicking factor VIII by binding both factors IXa and X. Although it reduces the frequency of bleeding episodes, there is
Externí odkaz:
https://doaj.org/article/79b73affbc374ae49b6af79c4ec9592d
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 27 (2021)
Factor (F) Xa inhibitors are safe and effective alternatives to warfarin. There are concerns about the lack of a reversal strategy in case of serious bleeds or need for emergency surgery in situations when the antidote andexanet alfa is not available
Externí odkaz:
https://doaj.org/article/95711c6afc094cf08491e6e6a03d341f
Autor:
Cedric Hermans, Jan Astermark, Manuela Carvalho, Gerry Dolan, Roseline d'Oiron, Pierre Fontana, Pål André Holme, Gili Kenet, Robert Klamroth, Maria Elisa Mancuso, Natascha Marquardt, Ramiro Nunez, Olga Katsarou, Ingrid Pabinger‐Fasching, Gabriele Quintavalle, Ryan Rodgers, Paul van der Valk, Jerzy Windyga, Victor Jimenez Yuste, Irena Preložnik Zupan
Publikováno v:
Haemophilia. 29:913-916
Publikováno v:
Haemophilia. 29:658-667
Introduction: Limited evidence exists on objectively measured habitual physical activity (PA) of young people with haemophilia (PWH). Aims: To compare different outcomes of objective PA between young PWH A and controls using a commercial activity tra
Autor:
Robert Klamroth, Cihan Ay, Philippe De Moerloose, Pierre Fontana, Jerzy Windyga, Jan Astermark, Erik Berntorp, Manuela Carvalho, Gerard Dolan, Cedric Hermans, Pål Andre Holme, Gili Kenet, Maria Elisa Mancuso, Natascha Marquardt, Ramiro Nunez, Ingrid Pabinger, Ryan Rodgers, Paul van der Valk, Victor Jimenez Yuste, Irena Preložnik Zupan
Publikováno v:
Haemophilia, Vol. 29, no.1, p. 21-32 (2023)
INTRODUCTION: As people with haemophilia (PWH) receive better treatment and live longer they are more likely to encounter cardiovascular disease (CVD) and other comorbidities. ESC guidelines for the acute management of patients presenting with acute